

Methods of Cancer Diagnosis, Therapy, and Prognosis

Volume 2

General Methods and Overviews, Lung Carcinoma and Prostate Carcinoma

Edited by

M.A. Hayat

Department of Biological Sciences,
Kean University, Union, NJ, USA



Springer

Editor
M.A. Hayat
Department of Biological Sciences
Kean University
Union, NJ
USA

ISBN 978-1-4020-8441-6 e-ISBN 978-1-4020-8442-3

Library of Congress Control Number: 2008930172

© 2008 Springer Science + Business Media B.V.

No part of this work may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher, with the exception of any material supplied specifically for the purpose of being entered and executed on a computer system, for exclusive use by the purchaser of the work.

Printed on acid-free paper

9 8 7 6 5 4 3 2 1

springer.com

New Insights into the Role of Infection, Immunity and Apoptosis in the Genesis of the Cancer Stem Cell

Peter Grandics

INTRODUCTION

Understanding the pathomechanism of cancer is of primary interest in medical research (Trosko and Rauch, 1998; Bjerkvig *et al.*, 2005). In the past century, several mechanisms were proposed. It was hypothesized that cancer arises from a single cell that loses its differentiated state through sequential mutations. This initiation-promotion-progression concept explains the steps in a sequential process. Later, this hypothesis led to the mutagenic and recently the oncogenic theories, which hypothesize that defects in tumor suppressor genes are responsible for the development of cancer. The impairment of cell-to-cell communication as a cause of cancer has also been postulated.

Environmental effects, such as chemical carcinogens or life style factors, such as alcohol or tobacco consumption or drug abuse, could also cause mutations and other genetic abnormalities observed in cancer cells. The discovery of the cancer stem cell lent support to the theory that cancer may develop from a single cell, and raised the question of cancer stem cells arising from normal stem cells. Indeed, if normal stem cells could undergo the type

of mutations observed in tumor cells, this would potentially compromise the genetic stability of the organism. Therefore, the likelihood that normal stem cells are very well protected is demonstrated by their resistance to radiation and toxins (Dean *et al.*, 2005).

One fascinating finding is that immunosuppressive cytotoxic antineoplastic therapies may, on occasion, cause the regression of a clinically established cancer. At first, applying this as a therapeutic strategy may seem counterintuitive, considering the fundamental role of the immune system in protecting the body against infectious organisms and aberrant cells. In addition, cancer itself is frequently immunosuppressive, so exacerbating a pre-existing immunosuppression may not seem like a rational strategy.

In this light, it appears paradoxical that the same degree of immunosuppression that is lethal in a bacterial or fungal infection actually benefits cancer suppression. In other words, the deletion of the T cell compartment that accompanies cytotoxic antineoplastic therapies may facilitate cancer regression (Mackall, 2000). This suggests that cancer itself may arise from the immune system, potentially from the

T cell compartment, which would explain why the suppression of cellular immunity could also lead to the suppression of the disease. Another observation is that tumor cells are poorly immunogenic, despite the fact that tumor cells are antigenic. Therefore, they do not generate a T cell-mediated immune response, and if so, it is of low intensity (Melial, 2000). If tumor cells were derived from injured lymphocytes, particularly T cells that still share some functional properties with their normal counterparts, an immune tolerance to cancer cells could be explained, as the immune system is not made to attack itself. In pathological situations, T cells do attack self-tissue in a manner reminiscent of the autoreactive nature of cancer cells, which have the ability to attack and invade host tissues. In other words, cancer cells behave like autoreactive lymphocytes. Here, we explore the evidence suggesting that such a mechanism could be at work during cancer development.

The prevalent genetic theories of cancer are built upon observations of genetic abnormalities in tumor cells. These theories do not generally take into account the demonstrated importance of environmental factors in human cancer development. In a previous article, Grandics (2003) has shown that specific dietary deficiencies mimic the effects of chemical or radiation damage to DNA, which we propose plays an important role in human carcinogenesis and tumorigenesis. This observation allows us to consider cancer as a single disease, possibly developing from a single cancer stem cell. Based on this observation, we could assume that the observed genomic abnormalities in cancer cells are an effect rather than the cause of the disease. This idea also points to the

direction of upstream events preceding the development of the malignant cell. We propose that identifying these events will be fundamental to understanding the pathomechanism of cancer. By exploring the functional similarities between lymphocytes and cancer cells, we provide an insight into this realm of possible upstream events.

The Exterior Cell Surface Layer (Cell Coat)

The lymphocyte cell coat is a labile structure, and the treatment of cells may lead to the loss of its components (Grandics, 2006a). This material plays an important role in lymphocyte functions including homing, cell mediated immunity, electrophoretic properties and antigen expression; cell surface proteins are thought to be involved in cell propagation and differentiation. After treatment with β -glucosidase, sialidase and trypsin, lymphocytes lose their homing abilities. Cytotoxic lymphocytes transiently lose their cytotoxic ability after a brief papain treatment. Lysis of the cell coat suppresses cell-mediated immunity. Treatment by glycosidases including neuraminidase affects the bodily distribution of lymphocytes and demonstrates alterations in their antigenicity. Treatment with trypsin and neuraminidase reversibly eliminates the mitogenic response of lymphocytes. The cell coat on thymocytes is significantly thicker than on splenic lymphocytes, suggesting a role for the cell coat in T cell function. The cell coat of the lymphocyte cell membrane has been characterized using various stains. These investigations found high acid mucopolysaccharide content with a significant number of acidic amino sugar end groups.

Cancer cells also exhibit an exterior cell surface coat. The similarities between the cell coat of normal and leukemic lymphocytes have been investigated. Pathological lymphocytes (CLL) have a uniformity of staining similar to their normal counterparts, with some differences observed with cationic stains that could be due to a decrease in the sialoprotein of the cell coat of CLL cells. With some similarity to lymphocytes, the tumor cell coat has been suggested to play a role in cell contact and adhesion, cell recognition, as well as the capacity to metastasize.

The tumor cell coat is also sensitive to neuraminidase and can rapidly regrow following treatment with the enzyme. The enzyme treatment also changes the immunological properties of tumor cells. Trypsin and EDTA remove the tumor cell coat. The cell coat is involved in the mechanism by which tumor cells escape cellular immune attack. The degradation of the cell coat by brief hyaluronidase treatment of glioma cells sensitizes them to cytotoxic lymphocyte attack. Although normal human glial cells also produce hyaluronic acid, glioma lines produce significantly more. Hyaluronidase-sensitive coats have been found on a variety of murine sarcoma and carcinoma cell lines. It appears that a mucopolysaccharide coat on tumor cells impedes the successful use of immunotherapy. It was demonstrated that the displacement of the tumor cell coat by charge-functionalized lipids or polycationic substances leads to tumor cell apoptosis and tumor destruction (Kovacs, 1983; Marquez *et al.*, 2004).

It has been demonstrated that the cell coat of lymphocytes and tumor cells are functionally significant. The degradation/ removal of cell coat significantly impacts the functionality of both tumor cells and lym-

phocytes; therefore, tumor cell isolation methods could alter the functionality of isolated cells. In other words, with the loss of the cell coat, lymphocytes lose fundamental functions, i.e., cannot attack target cells, while tumor cells also lose cell contact and adhesive properties, as well as the ability to metastasize. In addition, tumor cells become sensitive to apoptosis.

Activation of Coagulation

The activation of coagulation occurs during tissue injury as well as in various pathologies. Infection leads to both an inflammatory reaction and the activation of coagulation, as there is a crosstalk between these functions (Esmon, 2004). Blood coagulation components can inhibit or amplify the inflammatory response. Blood clotting is initiated when pathogenic components, such as endotoxin or inflammatory cytokines, induce synthesis of tissue factor on leukocytes. The coagulation cascade is subsequently triggered. The formation of negatively charged membrane phospholipid surfaces amplifies the coagulation reaction. Natural anticoagulant pathways, such as the protein C anticoagulant pathway, limit the coagulation process, thereby suppressing the inflammatory response, including reducing inflammatory cytokine secretion, decreasing NF- κ B signaling, minimizing leukocyte chemotaxis, endothelial cell interactions, and suppressing apoptosis.

Platelets are also involved in the link between inflammation and coagulation. Inflammatory cytokines such as IL-6 or IL-8 increase platelet production, and such platelets are more thrombogenic (Burstein, 1997). In addition, the platelets release the CD40L protein, a potent proinflammatory

mediator, which subsequently induces tissue factor synthesis and amplifies the secretion of proinflammatory cytokines. This, in turn, leads to a progressive cycle that ultimately can produce severe vascular and organ injury.

In 1865, Trousseau first described a cancer-associated condition now called migratory thrombophlebitis in which a spontaneous coagulation of the blood occurs in the absence of inflammatory reactions (Trousseau, 1865). It manifests as migratory thrombosis in the superficial veins of the chest wall and arms, but it can also occur in other sites. This condition is a variant of venous thromboembolism. Thrombosis is a frequent complication of malignancy, and thromboembolic death is the second leading cause of mortality in cancer (Donati, 1995). Malignant cells interact with the blood coagulation system by releasing procoagulant and fibrinolytic substances and inflammatory cytokines (Caine *et al.*, 2002). In addition, direct interaction with endothelial cells, monocytes/macrophages, and platelets also leads to localized clotting activation. Similar to normal activated inflammatory cells, malignant cells release tissue factor, which promotes the formation of fibrin deposits in the tumor cell microenvironment.

The fibrin gel matrix, along with other connective tissue components, form the basis for the tumor stroma, a matrix in which tumor cells are dispersed and which provides the vascular supply as well as a barrier against rejection by the cellular immune system. The tumor stroma shares properties with the temporary stroma of a healing wound (Dvorak, 1986). Similar to the fibrin coating on macrophages, the observed fibrin coating of tumor cells

is involved in the mechanism by which tumor cells escape destruction by NK cells. Histological evidence suggests that inflammatory lymphocytes are confined to the tumor-host interface, and do not significantly penetrate the tumor (Dvorak *et al.*, 1983). Malignant cells secrete inflammatory cytokines such as TNF- α and IL-1 β that downregulate the anticoagulant system of vascular endothelial cells (Caine *et al.*, 2002). The secretion of IL-8 promotes new blood vessel formation, and the fibrin deposited around tumor cells facilitates angiogenesis.

Tumor cells attach to the vascular endothelium and promote the adhesion of leukocytes and platelets. Monocytes and macrophages also home in on vascular surfaces due to inflammatory stimuli. In response to inflammatory molecules, complement, lymphokines and immune complexes, these cells subsequently secrete procoagulant tissue factor; tumor-associated macrophages express significantly higher levels of tissue factor than control cells. These macrophages also increase their fibrinolytic enzyme production.

Both human and animal cancers cause platelet aggregation *in vitro* and *in vivo* (Hejna *et al.*, 1999). The ability of tumor cells to aggregate platelets and secrete plasminogen activator correlates with their metastatic potential. Indeed, thrombocytopenia reduces the metastases of tumors as do compounds capable of reducing platelet aggregation. These include aspirin, prostaglandins and other nonsteroidal (NSAID) anti-inflammatory drugs. A reduced risk of fatal colon cancer has been observed among aspirin users (Thun *et al.*, 1991). Administration of heparin and fibrinolysis also reduces the incidence of experimental metastases, while the

administration of anti-fibrinolytic agents increases their incidence.

Cancer treatment by surgery, cytotoxic antineoplastic drugs, and hormonal therapy all contribute to the hypercoagulable state and risk factors for thromboembolism in cancer patients (Caine *et al.*, 2002). The risk of fatal pulmonary embolism increases four-fold after surgery in cancer patients. Chemotherapy drugs including cisplatin, mytomicin C and tamoxifen as well as high-dose and multi-drug regimes increase the risk of thrombotic complications. Prophylactic treatment with warfarin reduces this risk. The use of hematopoietic growth factors subsequent to chemotherapy was shown to induce thrombosis in breast cancer patients. Venous thrombosis could also be a marker for an otherwise asymptomatic cancer.

Similarly to a normal inflammatory reaction, activation of coagulation takes place in cancer. The events of tumor stroma development are comparable to wound healing (Dvorak, 1986), and it is possible that tumor formation may be associated with defective wound healing initiated by an inflammatory reaction due to infection and/or tissue injury. Therefore, we believe it is important to investigate potential links between infection, inflammation, and cellular immune response in searching for the origins of the cancer cell.

Infection and Inflammation

The etiological role of infectious agents has been indicated in various cancers (Grandics, 2006a). In 100 cases of human leukemia, *Mycoplasma*, *Salmonella*, *Micropolyspora*, *Mycobacterium*, *Absidia*, pseudorabies virus, and adenovirus antigens were commonly detected in the

patient's sera. Hepatotropic viruses (hepatitis B and C) cause hepatic necrosis followed by hepatocellular, B cell and gastric malignancies. Antiviral therapy of hepatitis C infection lead to the regression of virus-associated B cell lymphoma. Adenoviral infection has been associated with childhood leukemia and cytomegalovirus infection with testicular cancer. *Helicobacter pylori* infection is widespread in the population (an estimated 40–80% infected) and is linked to gastric cancer and mucosa-associated lymphoid tissue (MALT) lymphoma. A reversal of lymphoma-induced neutropenia has been observed with the eradication of *H. pylori* infection. Simian virus 40 (SV40) is associated with human brain cancers and non-Hodgkin's lymphoma. Ocular adnexal lymphoma is linked to *Chlamydia psittaci* infection, and the reversal of lymphoma was observed with pathogen-eradicating antibiotic therapy. The list continues: Cervical intraepithelial neoplasia (CIN) is associated with human papilloma virus (HPV) infection with a co-etiological presence of chronic bacterial cervicitis. *Mycoplasma* and HPV association were found to be dominating. The role of mycoplasma in the dysplasia of the uterine cervix and development of CIN has also been demonstrated.

Mycoplasmas are particularly interesting due to their widespread presence in the human population. Although many mycoplasmas are not directly pathogenic in humans, they are associated with many diseases. Mycoplasmas have co-leukemogenic activity, and are found to increase tumor cell invasiveness. In approximately half of the examined cases, mycoplasma DNA was present in ovarian and gastric carcinoma specimens. In gastric, lung, esophageal, breast, and colon cancers as well as glioma

specimens, *Mycoplasma hyorhinis* was detected in 50% of the cases. Mycoplasmas are known to cause chromosomal changes. Mixed *Mycoplasma pneumoniae* and influenza virus infection induce lung cancer in an animal model. The direct role of the AIDS-associated *Mycoplasma fermentans* and *Mycoplasma penetrans* in oncogenesis has been investigated. These mycoplasma strains induce gradual malignant transformations that eventually become irreversible. Besides its direct oncogenic potential, *Mycoplasma fermentans* exhibits a unique cytoidal effect on the undifferentiated myelomonocytic lineage, but not on differentiated myelomonocytic cells. The depletion of immature myelomonocytic cells likely contributes to the functional immunodeficiency present in cancer patients.

In response to pathogens, the host mounts a protective inflammatory response. Immune cells migrate to the area of infection and produce inflammatory messengers called cytokines. Initially, cells of the innate immune system (macrophages, neutrophils, NK cells) become involved, followed by the activation of cells of the adaptive immune system. These include antigen-presenting cells (APCs), T and B cells, which play an important role in propagating the inflammatory response. T cell inflammation plays a major role in antitumor immune responses. Key regulators of T cell-mediated response are the T helper (Th) cells that secrete the cytokines orchestrating this response. The two subtypes Th1 and Th2 cells produce cytokines stimulating cellular and humoral immune responses.

Intracellular pathogens (e.g., viruses and mycoplasmas) use the Toll-like receptor (TLR) signaling mechanism to escape host defenses (Netea *et al.*, 2004). Pathogen-

associated molecular patterns on the surface of mycoplasmas engage TLRs 1, 2, and 6 on the surface of APCs that lead to a Th2-type polarization of the immune response and the secretion of IL-10, IL-4, IL-5 and IL-13. These cytokines are antagonistic to Th1 type cytokines (TNF- α , IL-2, IFN- γ , IL-6, IL-12); excessive production of either type of cytokine upsets the homeostatic balance needed to maintain a proper mix of cellular and humoral immune responses (Hilleman, 2004). Utilizing this mechanism, mycoplasmas suppress cell-mediated immunity, which allows them to persist and predispose the host for colonization by other pathogens. The observation that leukemia patients were colonized by over half a dozen pathogens besides mycoplasmas (Grandics, 2006a) suggests that suppression of the cellular immune system provides a fertile ground for a variety of pathologies.

Besides regulating innate and adaptive immune responses, cytokines are involved in cell growth and differentiation (Grandics, 2006a). Normally, the secretion of cytokines is of short radius and limited duration, typically regulating self or adjacent cell functions. The activity of cytokines is tightly regulated, and there is evidence that cytokines contribute to inflammatory autoimmune diseases and malignancies. Similar to activated T cells, various tumor cells secrete immune response-polarizing cytokines (IL-10, IL-6, IL-8, IL-13, TGF- β) serving as autocrine and/or paracrine growth factors for the cancer. The progression of the disease and patient survival was correlated with increasing levels of cytokine secretion. This secretion is frequently constitutive, leading to elevated serum levels of cytokines in malignancies including melanoma, non-small cell lung carcinoma,

renal cell carcinoma, and bladder carcinoma. In addition, tumor cells can induce IL-10 in the tumor environment. IL-10, the most potent Th2 polarizing cytokine, suppresses the tumoricidal activity of macrophages, blocks presentation of tumor antigens to professional APCs, and inhibits tumor-specific cytotoxic T cells. However, in cancers both cellular and humoral immune response may be depressed, as in the absence of IL-4 production, IL-10 secretion alone cannot induce a Th2-type response.

It appears that the immune response becomes distorted at multiple levels during the development of cancer. First, infectious agents may act in concert to subvert cellular immunity, thereby upsetting the homeostatic balance of a proper mix of cellular and humoral immune response. This leads to an aberrant cytokine-signaling that results in depressed apoptosis and excessive proliferation (Grandics, 2006a). Cytokines seem to be the key substance of apoptosis of leukemic cells. Abnormal inflammatory cytokine secretion by tumor cells reinforces the existing imbalances and thus promotes disease progression. Similar to T cells, cancer cells use inflammatory cytokines as autocrine and paracrine growth factors, suggesting a functional relationship between cancer cells and cells of the immune system.

Infection, Autoimmunity, and Cancer

Several lines of evidence suggest a direct relationship among infection, autoimmunity, and cancer (Grandics, 2006a). Hepatitis B and C viruses are involved in an autoimmune condition that precedes the development of hepatocellular carcinoma. Data also demonstrate a higher prevalence of B-cell non-Hodgkin's

lymphoma in HCV-infected patients with autoimmune manifestations including Sjögren syndrome, cryoglobulinemia, and systemic lupus erythematosus (SLE). Adenovirus infection is associated with childhood leukemia, and family studies in acute childhood leukemia have shown possible associations with autoimmune disease. Epstein-Barr virus and human T lymphotropic virus type 1 infection are associated with abnormal lymphoproliferation and Hodgkin's lymphoma. Cytomegalovirus infection is linked to autoimmunity and testicular cancer. *H. pylori* infection can lead to autoimmune neutropenia and MALT-lymphoma in addition to its well-established role in the development of gastric cancer. Systemic rheumatic disease has also been linked to lymphoid malignancy. These findings underline a close relationship among infection, autoimmunity, and proliferative disorders, possibly mediated by abnormally functioning cytokine signaling.

Antinuclear antibodies (ANA) were demonstrated in the sera of 19% of patients with malignancies in the absence of overt autoimmune manifestations. In cancer patients, a large number of autoantibodies are observed against tissue-specific antigens, nucleoproteins, membrane receptors, proliferation-associated antigens, tissue-restricted antigens, etc. Autoantibodies to the p53 protein were detected in the sera of cancer patients before the onset of the disease. This raises the possibility that cancer is a specific autoimmune condition. Autoimmune connective tissue disorders are also commonly associated with malignancies. It was reported that gastric atrophy and pernicious anemia carry a risk for gastric carcinoma 18 times that of the population average. It appears that a variety of

infections may induce autoimmune serological features without overt autoimmune disease or organ involvement; however, this condition may progress to clinical autoimmune disease and malignancy if impaired T cell function prevails. Such condition develops at a higher frequency among the elderly.

It was observed 30 years ago that a low percentage of human T cells (3.4%) has the ability to form auto-rosettes with autologous erythrocytes; in breast cancer and melanoma patients, the ratio was elevated to 6.1% and 7.4%, respectively. This observation implied that some level of autoreactivity is normal, confirmed later by studies on T cell tolerance. However, the observation also pointed to an elevated level of autoreactive T cells involved in cancer. The mechanism of activation of an autoreactive T cell response was linked subsequently to bacterial and viral infections through the process of molecular mimicry in which pathogen-derived peptides mimic self-peptides. This phenomenon was studied in animal models and was supported by clinical observations. As a highlight, when lymphocytic choriomeningitis virus (LCV) antigens were expressed in the pancreas of transgenic mice, infection with the virus led to autoimmunity and diabetes.

H. pylori antigens mimic epitopes on H^+, K^+ -adenosine triphosphatase in the gastric mucosa, thereby activating cross-reactive gastric T cells. Viral peptides mimic sequences on myelin basic protein, leading to multiple sclerosis. Cytochrome c (cyt c) as an antigen was used to study how self-proteins prime autoreactive T cell responses, as SLE patients possess autoantibodies to cyt c. When non-self cyt c was coadministered with the self-

protein, B cells specific for the foreign antigen primed autoreactive T cells caused breaking tolerance to self-cyt c. The same autoimmune phenomenon occurs in the LCV transgenic mice when LCV antigens on pancreatic cells, and the intact virus antigens are copresented to the immune system. Therefore, it is quite likely that autoimmunity spontaneously develops during a variety of infections when antigens on microorganisms mimic self antigens and are presented together, breaking T cell tolerance.

The presence of autoreactive T cells has been observed in healthy persons, which indicates a role for these cells in immune defense (Grandics, 2006a). If autoreactive T cells were always absent in the T cell repertoire, the responsiveness toward foreign antigens that resemble self-antigens would be reduced. This notion is supported by the observation that T cells which recognize variants of self-antigen are of lower avidity than those recognizing a foreign antigen. Also, tolerance to self-antigen reduced T cell variants for these peptides as well as the diversity of T cell receptor α and β -chain sequences of self-specific T cells. It appears that some level of autoreactive T cells is necessary for immune defenses. Clinical autoimmunity may develop when persistent infection provides a continuing high dose of antigenic stimulus, and this situation could predispose patients to the development of proliferative disorders.

Defective Apoptosis

Normal tissue development requires damaged, dangerous or unnecessary cells to be eliminated while healthy cells survive. The survival of harmful or damaged

cells can lead to various pathologies. The evolutionarily conserved mechanism of apoptosis eliminates unwanted or abnormal cell populations (Grandics, 2006a). Lymphocytes require IL-2, IL-4, IL-7, IL-9, and IL-15 for viability, and withdrawal of these cytokines leads to apoptotic cell death. Leukemia patients who went into complete remission following chemotherapy developed a different type of leukemia after being placed on IL-2 therapy. IL-2 is an essential cytokine for the viability of activated T-cells, suggesting a link between the survival of activated T-cells and leukemic cells. Myeloid leukemia cells are also cytokine-dependent and undergo apoptotic cell death following cytokine withdrawal. Various immune response-polarizing cytokines that tumor cells secrete inhibit chemotherapy- or radiation-induced apoptosis. There are myeloid leukemia cell lines that have become independent of an external cytokine supply, but generally cytokines can protect both normal and cancer cells against apoptosis induced by various cytotoxic agents. The persistence of infectious agents and chronic inflammation in cancer patients promotes NF- κ B activation and inflammatory cytokine production, thereby contributing to the diminished apoptosis of abnormal cells.

The completion of immune response against pathogenic microorganisms requires the deletion of activated T and B cells that participate in the immune defenses, particularly self-reactive ones (although a fraction of them survive as memory cells). Apoptosis plays an important role in the regulation of peripheral immunity through the Fas/APO-1 cytotoxic pathway. Defective apoptosis can lead to autoimmune disease and cancer. As cancer cells are not immortal, they maintain a program for apoptotic cell death.

The apoptosis marker Fas receptor (FasR) is expressed on numerous cell types, whereas the Fas ligand (FasL) is mainly expressed on T cells. FasL mediates the apoptosis of effector T cells as part of an immune response termination and tolerance development. FasL is also expressed in “immune-privileged” tissues such as the brain, testes, and eyes with the purpose of preventing inflammation. Mutations in Fas or FasL can lead to autoimmune disease. Similar to cytotoxic T cells, various tumor cells also express FasL and use it to induce apoptosis of invading lymphocytes. Breast tumor cells express FasL that can kill Fas-sensitive lymphoid cells. The coexpression of Fas and FasL was observed in brain tumors that can use this mechanism to obtain a proliferating advantage by “counter-attacking” tumor-infiltrating activated Fas-sensitive T lymphocytes. Similar observations have been made in Ewing sarcoma, gastric cancer, cholangiocarcinoma, B cell chronic lymphocytic leukemia (B-CLL), colon adenocarcinoma, head and neck cancer, lung carcinoma, esophageal carcinoma, ovarian carcinoma, lymphoma, pancreatic carcinoma, melanoma, and other malignancies (Grandics, 2006a). Childhood glial tumor cells (but not normal cells) in the brain express the common leukocyte-associated antigen and Fas.

The expression of apoptosis-related molecules on the surface of both neoplastic cells and cytotoxic lymphocytes (CTL) in tumor specimens raises the question of whether neoplastic cells are formed from CTLs by a premature termination of the apoptotic mechanism. Indeed, neoplastic cells behave like CTLs in their expression of FasL and in the induction of apoptotic death of activated T cells, as well as other cancer cells carrying

a functional FasR. In other words, cancer cells continue to act like T cells performing their immune-regulating functions.

Discussion and Therapeutic Implications

Infections by various pathogenic micro-organisms are a common occurrence in humans and other animals. In response to invading pathogen(s), an inflammatory reaction develops in the host organism. Initially, the innate immune system becomes involved, followed by the development of an adaptive immune response. Activated leukocytes produce inflammatory cytokines and chemokines as well as other growth factors aimed at clearing up the infection and facilitating tissue healing. The inflammatory reaction at the infection site triggers a variety of physiological responses. Antigen-presenting cells activate T and B cells in response to molecular patterns expressed on the surfaces of pathogenic microorganisms. Intracellular pathogens are overcome by the cellular immune response; in addition, the T cell inflammatory reaction is also key to antitumor immunity. Activated T helper 1 (Th1) cells secrete specific cytokines orchestrating this response.

Pathogenic microorganisms, however, have evolved strategies to evade immune surveillance in order to persist in the host. Several intracellular pathogens including mycoplasmas and viruses deploy molecular patterns on their surfaces that trigger a Th2-type (humoral) immune response and consequently depress cellular immunity. In addition, some infections such as the mycoplasmas remain sub-clinical, and by subverting the cellular immune response, these microorganisms predispose the host

for colonization by other pathogens eventually leading to various pathologies.

Molecular mimicry is initiated when viruses integrate host genes within their genome, (Tyler and Fields, 1996) and pathogens with host-like genes may have a survival advantage over those lacking such traits. Animal viruses are capable of fusing with prokaryotic cells that may facilitate gene transfer between distant microbial taxa (Citovsky *et al.*, 1988). Influenza virus hemagglutinin A sequences have been located in the p37 protein of *Mycoplasma hyorhinis*, and this protein increases tumor cell invasiveness (Ketcham, 2005). The exchange of genes among various micro-organisms (Lawrence, 2006) leads to the development of antibiotic resistance. Gene uptake also occurs by phagocytosis of apoptotic bodies while High Mobility Group (HMG) proteins, commonly associated with human DNA, may facilitate this process in bacteria (Grandics, 2006a).

When antigens from pathogens mimic self-antigens in the process of molecular mimicry, cross-reactive T cells may be generated. The study on breaking T cell tolerance with co-administered foreign and self-cytochrome c is a sobering reminder of just how easy it is to induce autoimmunity. However, evidence also demonstrates that a low level of autoimmunity is normal and necessary to mount an effective immune response to infections. Clinical autoimmunity may develop if a continuing high-dose antigenic stimulus persists, as in cases of chronic infection. In addition, there is also evidence that autoimmunity can lead to proliferative disorders.

As discussed, normal tissue development requires the elimination of dangerous and abnormal cells, and autoimmune T cells belong to this category. With the

completion of the immune response, the evolutionarily conserved mechanism of apoptosis eliminates effector T cells, leading to immune response termination and tolerance development. However, defective apoptosis can lead to autoimmunity and cancer.

We propose that an aberration in the apoptosis process leads to formation of the cancer stem cell from autoreactive T cells. In support of this observation, *Helicobacter*-induced gastric epithelial carcinoma was found to originate from bone marrow-derived cells (Houghton, 2004). This is the direct proof of cancer that does not arise from mutated epithelial cells. Also, the cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), a regulator of the effector function of T cells, is expressed in various leukemias and solid tumors (Contardi *et al.*, 2005). This suggests a link between CTLs, hematopoietic neoplasias and solid tumors.

Further evidence: the common acute lymphoblastic leukemia antigen was detected on glioma and melanoma cell lines (Grandics, 2006a). The melanoma-associated PRAME antigen is expressed both in leukemias and some solid tumors. The majority of leukemia and lymphoma cells test positive for the leukocyte common antigen. Seminoma, rhabdomyosarcoma, and some metastatic undifferentiated and neuroendocrine carcinomas have also been found to express CD45. The myeloid antigen Leu-7, typically expressed on natural killer (NK) cells and T cell subsets, was detected on small cell lung carcinoma and a variety of other solid tumors including astrocytoma, neuroblastoma, retinoblastoma, carcinoid tumors, etc. Neoplastic cells of Hodgkin's disease expressing Leu-7 may be related to NK cells or T

cells rather than B cells (Grandics, 2006a). We propose that the unexpected presence of some T cell markers on cancer cells may provide an insight into their origins. In addition, the observation that cancer stem cells embedded in an environment of normal host tissue can undergo a differentiation process (during which surface markers of lymphoid origin disappear) explains the absence of leukocyte-derived surface antigens in some solid tumors.

In benign colonic adenomatous polyps and synchronous adenocarcinoma, comparable and very large numbers of genomic alterations ($> 10,000$ events per cell) were found (Stoler *et al.*, 1999), demonstrating massive genomic damage characteristic of apoptosis as opposed to sequential mutations. In addition, this demonstrates that genomic instability precedes the development of a malignant state, indicating that malignancy is an effect rather than the cause of genetic abnormalities in cancer cells. It is therefore reasonable to conclude that there is no fundamental difference between benign and malignant tumors, and that possibly a very small difference in the disregulation of proliferative controls leads to a malignant phenotype.

We further propose that the resultant cancer stem cell still preserves some functions of an effector T cell, such as homing in to sites of inflammation such as the inflamed bronchi of a cigarette smoker, the damaged liver of an alcohol abuser, an *H. pylori*-infected gastric mucosa, an HPV-infected uterine cervix, an inflamed colon, etc. The cancer cell retains some capabilities of an effector T cell to secrete inflammatory cytokines (even if in an aberrant, constitutive fashion), thereby distorting local immune responses, disabling cytotoxic T cells and diminishing apoptosis in its environment.

Like normal activated inflammatory cells, cancer cells activate the coagulation system, leading to the formation of the tumor stroma in which tumor cells proliferate. Dvorak (1986) in his paper entitled "Tumors: wounds that do not heal" succinctly described similarities between the formation of the temporary stroma of a healing wound and tumor stroma development. While the cancer cell continues to act as if it participated in a wound healing process, it actually enlarges the wound stroma due to its constitutive secretion of tissue factor, inflammatory cytokines and other growth factors, which also provide stimuli for the propagation of the malignant cells. This leads to an ever-continuing cycle of tumor growth.

Every human cell has the ability to repair itself, and cancer cells retain some of this capacity (Degos, 1992). As cancer stem cells exhibit plasticity similar to normal stem cells, we propose that a cell-to-cell communication between cancer stem cells and surrounding host tissues allows tumor cells to develop varying degrees of differentiated phenotypes resembling cells of normal differentiated tissues. This in turn leads to the emergence of various tumor types and creates the illusion of a great multitude of cancers.

It has been long known that cancer cells, besides growing inside tumors, also circulate in the blood (Griffiths *et al.*, 1973). This is easy to rationalize if cancer cells are indeed damaged autoreactive T cells, and also provides an explanation for metastasis formation. Cancer cells interact with neutrophils, macrophages and platelets that lead to the formation of micrometastases that can remain in the blood for a long time. These aggregates persist even after adjuvant chemotherapy, although in

reduced numbers. Larger cell clumps are more effective in promoting metastases than smaller ones (Grandics, 2006a). With the progression of inflammation in cancer patients, the circulating micrometastases find new sites of proliferation that lead to the formation of metastases.

Current cancer therapies are tumor-centric, as tumors are equated with cancerous disease. Main therapeutic modalities include the surgical removal of tumors as well as radiation and chemotherapies. All of these contribute to the hypercoagulable state and risk of thromboembolism, which have a significant negative impact on the morbidity and mortality of cancer patients. If tumor cells did originate from T cells, any therapeutic approach targeting tumor cells will likely diminish T cell function. Cytotoxic antineoplastic therapy represents an extreme situation in this regard, resulting in the deletion of even resting T cells, the reconstitution of which takes several months (Mackall, 2000). This makes the combination of chemotherapy and immunotherapy an unrealistic proposition.

If cancer cells indeed originate from damaged autoreactive T cells, our current views on cancer immunotherapy need to be revised. The immune system was not developed to attack itself, and this is supported by the unresponsiveness of the cellular immune system to cancer even if tumor cells are antigenic. When we attempt to induce an immune response against tumors, we run the risk of developing autoimmune disease (Tirapu *et al.*, 2002) and ultimately, secondary malignancies.

The suppression of the immune system by chemotherapeutic agents and radiation encourages the propagation of microbial and parasitic infections already present in cancer

patients. However, pathogenic microorganisms are intimately involved as coetiological agents in the development of various malignancies via molecular mimicry-induced autoimmunity, and maintain a cytokine milieu that favors proliferation as opposed to apoptosis. Therefore, current immunosuppressive cancer therapies may establish the conditions for disease recurrence as well as the emergence of new primary tumors, which is in fact, a common experience. Also, the cancer patient's system appears to retain a "memory" of the disease as the risk of developing another cancer is higher than those who have never had the disease. This memory could be attributed to autoimmune memory T cells, reactivated by recurrent infections which become cancerous later on as a consequence of defective apoptosis.

The eradication of pathogens could have a favorable effect on the course of malignant diseases, as demonstrated by therapies of HCV, *H. pylori*, and *Chlamydia psittaci* infections (Grandics, 2006a). Mycoplasmas are difficult to eradicate and require high-dose, long-term antibiotic therapies, but even after that the pathogens are found to persist. There are no therapies for many viral infections at this time. With our new understanding of the mechanism of TLR signaling, opportunities have opened for overcoming these types of pathogens. Recently, a therapeutic oral mycoplasma vaccine was described (Szathmary, 2005) the principle of which could be utilized for the therapy of other intracellular infections.

If defective apoptosis of autoreactive T cells leads to the emergence of the cancer stem cell, our research must focus on the physiological events associated with apoptosis. Any therapeutic approach upstream from this step is merely symptomatic,

and offers little hope of defeating cancer. A century of accumulated evidence on the use of immunosuppressive cancer therapies supports this observation.

It was demonstrated that the exterior mucopolysaccharide cell surface coat on cancer cells protects them from apoptosis (Gately, 1982). Kovacs has explored this understanding to the greatest degree by synthesizing unsaturated aminolipids capable of displacing the cell coat on tumor cells (Kovacs, 1983). Administration of these compounds led to the apoptotic death of a variety of tumor cells *in vitro* and *in vivo*. Normal lymphocytes are less sensitive to the apoptotic effects of a fatty acid mixture than leukemic cells, although they do show some sensitivity (Otton and Curi, 2005). This observation may explain why the continuing administration of synthetic unsaturated aminolipids led to a diminishing efficacy of the therapy (Kovacs, 2006 personal communication), as normal lymphocytes are also surrounded by an exterior cell surface layer coat essential for their functions.

Endocrine hormonal signaling also affects apoptosis. Corticosteroids facilitate the apoptosis of lymphocytes and exert an immunosuppressive effect when the organism is subject to prolonged stress. Stress also down-regulates the digestive functions of the gut, including those of the stomach and pancreas. This in turn suppresses the uptake of critical nutrients that are essential for genomic stability (Grandics, 2003). It was found that breast cancer patients as a group exhibit a depressed thyroid function, suggesting an etiological role for thyroid deficiency in neoplasia. Thyroid function is profoundly affected by the iodine supply, and thyroid, breast and gastric cancers have been linked

to iodine deficiency (Grandics, 2003). We have also pointed out that critical nutrient deficiencies mimic the effects of chemical or radiation damage to DNA, and suggested that the correction of these deficiencies could reverse the progression of malignant proliferation.

In the past century, insufficient attention was paid to the role of dietary factors in the development and progression of malignant diseases. No Recommended Daily Allowances (RDAs) are available for a number of essential nutrients, and where available, the RDA is of questionable value. Iodine, a vital micronutrient, is an example: the current WHO recommendation for iodine is 0.15 mg/day. However, some Japanese consume as much as 50–80 mg of iodine/day through their seaweed rich diet and exhibit significantly lower rates of the major cancer types than seen in the Western world (Grandics, 2003, 2006a). In addition, iodine supplementation clinical trials with school children have demonstrated that an iodine intake vastly exceeding the RDA (more than 6,000 times higher) was both safe and clinically useful (Benmiloud, 1994). This could not possibly be the case if the RDA for iodine had been correctly determined. Similar clinical observations were made for high-dose administration of folate and vitamin B₁₂ (Heimburger et al., 1988) as well as vitamin C (Gonzalez et al., 2005). These findings question the accuracy of dietary RDAs, and suggest that current domestic as well as EU regulatory initiatives aimed at restricting the active ingredient contents in vitamin supplements are based on an erroneous scientific rationale.

It is also important to recognize that vitamin and mineral levels have significantly declined over the past 60 years

in our food supply (Worthington, 2002) possibly due to intensive agricultural production methods and industrial food processing. Experience teaches us that in the Western world, despite an abundance of food, people have difficulties in meeting their nutritional needs, demonstrated by now-rampant obesity as well as the historically proven explosion of degenerative diseases including cardiovascular diseases, diabetes and cancer. This suggests that we are still far from understanding the dietary needs of the human organism.

It is known that diabetics develop malignancies at a higher frequency than the population average (Strickler, 2001), which implicates pancreatic dysfunction in the etiology of cancer. Besides secreting digestive enzymes, the pancreas is also a source of hormonal regulators. We hypothesize that a combined effect of adrenal, thyroid and pancreatic dysfunction may predispose patients for neoplasia in a process promoted by dietary deficiencies as well as lifestyle factors including prolonged stress, poor hygiene, smoking, alcoholism and drug abuse, all of which are known to subvert immunity. It appears that we need to make the most important scientific discoveries in the simplest things, i.e., how to conduct our lives in a manner optimal for well-being. Therefore, the main operative principle of health care should be prevention.

To finally defeat cancer, our research needs to focus on the identification of those endocrine-signaling mechanisms that enable CTLs to complete their mission of apoptotic elimination of autoreactive T cells. We must abandon our focus on the tumor cell as far as the development of cancer therapeutics are concerned, as the destruction of cancer itself negatively impacts the immune system, thereby reactivating

the vicious cycle of infection, autoimmunity and malignancy that ultimately dooms cancer patients. By redirecting our focus toward physiological events preceding the formation of the cancer stem cell, we will be able to overcome this scourge that has haunted humanity since time immemorial. A systemic approach described in our previous articles (Grandics, 2003, 2006b) offers an alternative to current cancer therapies that works with the immune system, and which helps to reestablish homeostatic balance in the human body.

SUMMARY

This review explored similarities between lymphocytes and cancer cells based on which we propose a new model for the genesis of human cancer. We suggest that the development of cancer requires infection(s) during which antigenic determinants from pathogens mimicking self-antigens are copresented to the immune system, leading to breaking T cell tolerance. Some level of autoimmunity is normal and necessary for effective pathogen eradication. However, autoreactive T cells must be eliminated by apoptosis when the immune response is terminated. Apoptosis can be deficient in the event of a weakened immune system, the causes of which are multifactorial. Some autoreactive T cells suffer genomic damage in this process, but manage to survive. The resulting cancer stem cell still retains some functions of an inflammatory T cell, so it seeks out sites of inflammation inside the body. Due to its defective, constitutive production of inflammatory cytokines and other growth factors, a stroma is built at the site of inflammation similar to the temporary stroma built during wound healing. The

cancer cells grow inside this stroma, forming a tumor that provides their vascular supply and protects them from cellular immune response.

As cancer stem cells have plasticity comparable to normal stem cells, interactions with surrounding normal tissues cause them to give rise to all the various types of cancers, resembling differentiated tissue types. Metastases form an advanced stage of the disease, with the proliferation of sites of inflammation inside the body following a similar mechanism. Immunosuppressive cancer therapies inadvertently reinvigorate pathogenic microorganisms and parasitic infections common to cancer, leading to a vicious cycle of infection, autoimmunity, and malignancy that ultimately dooms cancer patients. Based on this new understanding, we recommend a systemic approach to the development of cancer therapies that supports rather than antagonizes the immune system.

REFERENCES

Benmiloud, M., Chaouki, M.L., Gutkunst, R., Teichert, H.M., Wood, W.G., and Dunn, J.T. 1994. Oral iodized oil for correcting iodine deficiency: optimal dosing and outcome indicator selection. *J. Clin. Endocrinol. Metab.* 79: 20–24.

Bjerkvig, R., Tysnes, B.B., Aboody, K.S., Najbauer, J., and Terzis, A.J.A. 2005. The origin of the cancer stem cell: current controversies and new insights. *Nat. Rev. Cancer* 5: 899–904.

Burstein, S.A. 1997. Cytokines, platelet production and hemostasis. *Platelets* 8: 93–104.

Caine, G.J., Stonelake, P.S., Lip, G.Y.H., and Kehoe, S.T. 2002. The hypercoagulable state of malignancy: pathogenesis and current debate. *Neoplasia* 6: 465–473.

Citovsky, V., Rottem, S., Nussbaum, O., Laster, Y., Rott, R., and Loyter, A. 1988. Animal viruses are able to fuse with prokaryotic cells. Fusion between Sendai or influenza virions and Mycoplasma. *J. Biol. Chem.* 263: 461–467.

Contardi, E., Palmisano, G.L., Tazzari, P.L., Martelli, A.M., Fala, F., Fabbi, M., Kato, T., Lucarelli, E., Donati, D., Polito, L., Bolognesi, A., Ricci, F., Salvi, S., Gargaglione, V., Mantero, S., Alberghini, M., Ferrara, G.B., and Pistillo, M.P. 2005. CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction. *Int. J. Cancer* 117: 538–550.

Dean, M., Fojo, T., and Bates, S. 2005. Tumour stem cells and drug resistance. *Nat. Rev. Cancer* 5: 275–284.

Degos, L. 1992. All-trans-retinoic acid treatment and retinoic acid receptor alpha gene rearrangement in acute promyelocytic leukemia: a model for differentiation therapy. *Int. J. Cell. Cloning* 10: 63–69.

Donati, M.B. 1995. Cancer and thrombosis: from phlegmasia alba dolens to transgenic mice. *Thromb. Haemost.* 74: 278–281.

Dvorak, H.F. 1986. Tumor: wounds that do not heal. *N. Engl. J. Med.* 315: 1650–1659.

Dvorak, H.F., Senger, D.R., and Dvorak, A.M. 1983. Fibrin as a component of the tumor stroma: origins and biological significance. *Cancer Metastasis Rev.* 2: 41–73.

Esmon, T.C. 2004. Interactions between the innate immune system and blood coagulation systems. *Trends Immunol.* 25: 536–542.

Gately, M.K., Glaser, M., McCarron, R.M., Dick, S.J., Dick, M.D., Mettetal, R.W., and Kornblith, P.L. 1982. Mechanisms by which human gliomas may escape cellular immune attack. *Acta Neurochir.* 64: 175–197.

Gonzalez, M.J., Miranda-Massari, J.R., Mora, E.M., Guzman, A., Riordan, N.H., Riordan, H.D., Casciari, J.J., Jackson, J.A., and Roman-Franco, A. 2005. Ascorbic acid and cancer 25 years later. *Integrative Cancer Ther.* 4: 35–44.

Grandics, P. 2003. Cancer: a single disease with a multitude of manifestations? *J. Carcinog.* 2: 9.

Grandics, P. 2006a. The cancer stem cell: evidence for its origin as an injured autoreactive T cell. *Mol. Cancer* 5: 6.

Grandics, P. 2006b. Complete remission achieved in a case of adult acute myelogenous leukemia by a novel nutritional therapy. *J. Altern. Complement Med.* 12: 311–315.

Griffiths, J.D., McKinna, J.A., Rowbotham, H.D., Tsolakidis, P., and Salsbury, A.J. 1973. Carcinoma of the colon and rectum: circulating malignant cells and five-year survival. *Cancer* 31: 226–236.

Heimburger, D.C., Alexander, C.B., Birch, R., Butterworth, C.E. Jr., Bailey, W.C., and Krumdieck, C.L. 1988. Improvement in bronchial squamous cell metaplasia in smokers treated with folic acid and vitamin B-12. Report of a preliminary randomized, double-blind intervention trial. *JAMA* 259: 1525–1530.

Hejna, M., Raderer, M., and Zelinski, C.C. 1999. Inhibition of metastases by anticoagulants. *JNCI* 91: 22–36.

Hilleman, M.R. 2004. Strategies and mechanisms for host and pathogen survival in acute and persistent viral infections. *Proc. Natl. Acad. Sci. USA* 101: 14560–14566.

Houghton, J., Stoicov, C., Nomura, S., Rogers, A.B., Carlson, J., Li, H., Cai, X., Fox, J.G., Goldenring, J.R., and Wang, T.C. 2004. Gastric cancer originating from bone marrow-derived cells. *Science* 306: 1568–1571.

Ketcham, C.M., Anai, S., Reutzel, R., Sheng, S., Schuster, S.M., Brenes, R.B., Agbandje-McKenna, M., McKenna, R., Rosser, C.J., and Boehlein, S.K. 2005. p37 Induces tumor invasiveness. *Mol. Cancer Ther.* 4: 1031–1038.

Kovacs, A. 1983. Process for the preparations of anti-tumor therapeutics. *Hungarian Patent No. 200093 B.*

Kovacs, A. 2006. Personal communication.

Lawrence, J.G. 2005. Horizontal and vertical gene transfer: the life history of pathogens. *Contrib. Microbiol.* 12: 255–271.

Mackall, C.L. 2000. T-cell immunodeficiency following cytotoxic antineoplastic therapy: A review. *Stem Cells* 18: 10–18.

Marquez, M., Nilsson, S., Lennartsson, L., Liu, Z., Tammela, T., Raitanen, M., and Holmberg, A.R. 2004. Charge-dependent targeting: Results in six tumor cell lines. *Anticancer Res.* 24: 1347–1352.

Melief, C.J., Toes, R.E., Medema, J.P., Van der Burg, S.H., Ossendorp, F., and Offringa, R. 2000. Strategies for immunotherapy of cancer. *Adv. Immunol.* 75: 235–282.

Netea, M.G., Van der Meer, J.W.M., and Kullberg, B.-J. 2004. Toll-like receptors as an escape mechanism from host defense. *Trends Microbiol.* 12: 484–488.

Otton, R., and Curi, R. 2005. Toxicity of a mixture of fatty acids on human blood lymphocytes and leukaemia cell lines. *Toxicol. In Vitro* 19: 749–755.

Stoler, D.L., Chen, N., Basik, M., Kahlenberg, M.S., Rodriguez-Bigas, M.A., Petrelli, N.J., and Anderson, G.R. 1999. The onset and extent of genomic instability in sporadic colorectal tumor progression. *Proc. Natl. Acad. Sci. USA* 96: 15121–15126.

Strickler, H.D., Wylie-Rosett, J., Rohan, T., Hoover, D.R., Smoller, S., Burk, R.D., and Yu, H. 2001. The relation of type 2 diabetes and cancer. *Diabetes Technol. Ther.* 3: 263–274.

Szathmary, S. 2005. Immunomodulation of pathogen-host interactions, PhD Thesis, Szent Istvan University, Faculty of Veterinary Medicine, Budapest, Hungary.

Thun, M.J., Namboodiri, M.M., and Heath, C.W. Jr. 1991. Aspirin use and reduced risk of fatal colon cancer. *N. Engl. J. Med.* 325: 1593–1596.

Tirapu, I., Mazzolini, G., Rodriguez-Calvillo, M., Arina, A., Palencia, B., Gabari, I., and Melero, I. 2002. Effective Tumor Immunotherapy: start the engine, release the brakes, step on the gas pedal, and get ready to face autoimmunity. *Arch. Immunol. Ther. Exp.* 50: 13–18.

Trosko, J.E. and Rauch, R.J. 1998. Cell-cell communication in carcinogenesis. *Front. Biosci.* 3: 208–236.

Trousseau, A. 1865. Phlegmasia alba dolens. In: *Clinique Medicale de l'Hotel-Dieu de Paris*, vol. 3, 2nd edn. Balliere, Paris: 654–712.

Tyler, K.L., and Fields, B.N. 1996. Pathogenesis of viral infections. In: *Fields Virology*, Fields B.N., Knipe D.M., Howley P.M. Eds. Philadelphia, Lippincott-Raven: 173–203.

Worthington, V. 2002. Analyzing data to compare nutrients in conventional versus organic crops. *J. Altern. Complement Med.* 8: 529–532.